Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
Vermorken, J B × Peyrade, F Krauss, J Mesía, R Remenar, E Gauler, T C Keilholz, U Delord, J P Schafhausen, P Erfán, J Brümmendorf, T H Iglesias, L Bethe, U Hicking, C Clement, Paul #
Kluwer Academic Publishers
Annals of Oncology vol:25 issue:3 pages:682-8
Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin. Cilengitide selectively inhibits αvβ3 and αvβ5 integrins and is investigated as a treatment strategy.